These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37144549)

  • 1. Robust time selection for interim analysis in the Bayesian phase 2 exploratory clinical trial.
    Feng B; Zee B
    J Biopharm Stat; 2024 May; 34(3):413-423. PubMed ID: 37144549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian optimal phase II designs with dual-criterion decision making.
    Zhao Y; Li D; Liu R; Yuan Y
    Pharm Stat; 2023; 22(4):605-618. PubMed ID: 36871961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility-Based Dose Selection for Phase II Dose-Finding Studies.
    Aouni J; Bacro JN; Toulemonde G; Colin P; Darchy L
    Ther Innov Regul Sci; 2021 Jul; 55(4):818-840. PubMed ID: 33851358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible Bayesian subgroup analysis in early and confirmatory trials.
    Bunn V; Liu R; Lin J; Lin J
    Contemp Clin Trials; 2020 Nov; 98():106149. PubMed ID: 32942055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian approach to pilot-pivotal trials for bioequivalence assessment.
    Lv D; Grayling MJ; Zhang X; Zhao Q; Zheng H
    BMC Med Res Methodol; 2023 Dec; 23(1):301. PubMed ID: 38114931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology.
    Montazerhodjat V; Chaudhuri SE; Sargent DJ; Lo AW
    JAMA Oncol; 2017 Sep; 3(9):e170123. PubMed ID: 28418507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive designs in critical care trials: a simulation study.
    Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
    BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision-theoretic designs for small trials and pilot studies: A review.
    Hee SW; Hamborg T; Day S; Madan J; Miller F; Posch M; Zohar S; Stallard N
    Stat Methods Med Res; 2016 Jun; 25(3):1022-38. PubMed ID: 26048902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.